However, the evidence presented here that caspase-7 is involved in APP proteolysis, as well as the previously reported observation that caspase-7 is up-regulated early in the clinical progression of dementia [16], suggests that caspase-specific inhibitors have the potential to modulate disease progression and neurodegeneration by preventing alternative processing of APP. Here, CASP7 is linked to dementia.